Details of the Drug

General Information of Drug (ID: DM5XPIJ)

Drug Name
Leuprolide
Synonyms Enantone; Eligard (TN); Leuprorelin (INN); Viadur (TN); 5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
Indication
Disease Entry ICD 11 Status REF
Plasma cell myeloma 2A83.1 Approved [1]
Prostate cancer 2C82.0 Approved [2]
Endometriosis GA10 Investigative [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Sequence
>Leuprolide
PHWSYLLR
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1209.4
Logarithm of the Partition Coefficient (xlogp) 0.7
Rotatable Bond Count (rotbonds) 32
Hydrogen Bond Donor Count (hbonddonor) 15
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 4.6 - 212 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4-5 h [3]
Clearance
The sytemic clearance of drug is 7.6-8.3 L/h [4]
Elimination
Following administration of 3.75 mg leuprolide depot suspension to three patients, less than 5% of the initial dose was recovered as unchanged or pentapeptide metabolite in the urine.[L10310, L13781, L13784, L13814] [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours [4]
Vd
The volume of distribution (Vd) of drug is 27 L [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Thyroid disorder Not Available TPO OTJJLL20 [5]
Thyroid disorder Not Available bab2 OTNNK0KI [5]
Thyroid hyperfunction disorders Not Available SERPINA7 OTUYVTSU [5]
Chemical Identifiers
Formula
C59H84N16O12
IUPAC Name
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Canonical SMILES
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
InChI
InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
InChIKey
GFIJNRVAKGFPGQ-LIJARHBVSA-N
Cross-matching ID
PubChem CID
657181
ChEBI ID
CHEBI:6427
CAS Number
53714-56-0
DrugBank ID
DB00007
TTD ID
D0U5FF
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leutinizing-hormone-releasing hormone (GNRH1) TT0ID4A GON1_HUMAN Activator [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Protein bric-a-brac 2 (bab2) OTNNK0KI BAB2_DROME Drug Response [5]
Thyroid peroxidase (TPO) OTJJLL20 PERT_HUMAN Drug Response [5]
Thyroxine-binding globulin (SERPINA7) OTUYVTSU THBG_HUMAN Drug Response [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Leuprolide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Leuprolide and Ivosidenib. Acute myeloid leukaemia [2A60] [7]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Midostaurin. Acute myeloid leukaemia [2A60] [8]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Idarubicin. Acute myeloid leukaemia [2A60] [8]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Daunorubicin. Acute myeloid leukaemia [2A60] [8]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Gilteritinib. Acute myeloid leukaemia [2A60] [8]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Oliceridine. Acute pain [MG31] [8]
Terfenadine DM4KLPT Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [8]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Tacrine. Alzheimer disease [8A20] [9]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Rivastigmine. Alzheimer disease [8A20] [9]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Donepezil. Alzheimer disease [8A20] [9]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Leuprolide and Metronidazole. Amoebiasis [1A36] [10]
Ranolazine DM0C9IL Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Ranolazine. Angina pectoris [BA40] [8]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Leuprolide and Bepridil. Angina pectoris [BA40] [9]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Leuprolide and Dronedarone. Angina pectoris [BA40] [9]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Leuprolide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [11]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [8]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Promazine. Appearance/behaviour symptom [MB23] [8]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Cilostazol. Arterial occlusive disease [BD40] [8]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Voriconazole. Aspergillosis [1F20] [8]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Posaconazole. Aspergillosis [1F20] [8]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Levalbuterol. Asthma [CA23] [12]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Terbutaline. Asthma [CA23] [13]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Pirbuterol. Asthma [CA23] [13]
Isoetharine DMITSEH Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Isoetharine. Asthma [CA23] [13]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Salbutamol. Asthma [CA23] [12]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Formoterol. Asthma [CA23] [13]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [8]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [8]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Desipramine. Attention deficit hyperactivity disorder [6A05] [8]
Oxytocin DMDL27I Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Oxytocin. Autism spectrum disorder [6A02] [8]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Ofloxacin. Bacterial infection [1A00-1C4Z] [8]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [8]
Erythromycin DM4K7GQ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Erythromycin. Bacterial infection [1A00-1C4Z] [8]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Clarithromycin. Bacterial infection [1A00-1C4Z] [8]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Leuprolide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [9]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Leuprolide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [14]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Norfloxacin. Bacterial infection [1A00-1C4Z] [8]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Levofloxacin. Bacterial infection [1A00-1C4Z] [8]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Leuprolide and Moxifloxacin. Bacterial infection [1A00-1C4Z] [15]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [8]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Telithromycin. Bacterial infection [1A00-1C4Z] [8]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Retigabine. Behcet disease [4A62] [8]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Loperamide. Bowel habit change [ME05] [16]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Eribulin. Breast cancer [2C60-2C6Y] [8]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Lapatinib. Breast cancer [2C60-2C6Y] [8]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Tamoxifen. Breast cancer [2C60-2C6Y] [8]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Leuprolide and Toremifene. Breast cancer [2C60-2C6Y] [9]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Bosutinib. Breast cancer [2C60-2C6Y] [8]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Leuprolide and Grepafloxacin. Bronchitis [CA20] [14]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Leuprolide and Sotalol. Cardiac arrhythmia [BC9Z] [9]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Leuprolide and Dofetilide. Cardiac arrhythmia [BC9Z] [9]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [8]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [13]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [12]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [13]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [13]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Oxaliplatin. Colorectal cancer [2B91] [8]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Isoproterenol. Conduction disorder [BC63] [12]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Halothane. Corneal disease [9A76-9A78] [8]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Propofol. Corneal disease [9A76-9A78] [17]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Sevoflurane. Corneal disease [9A76-9A78] [8]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Probucol. Coronary atherosclerosis [BA80] [8]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Leuprolide and Methadone. Cough [MD12] [9]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Clofazimine. Crohn disease [DD70] [8]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Leuprolide and Mifepristone. Cushing syndrome [5A70] [9]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Leuprolide and Pasireotide. Cushing syndrome [5A70] [9]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Osilodrostat. Cushing syndrome [5A70] [8]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Sertraline. Depression [6A70-6A7Z] [8]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Trimipramine. Depression [6A70-6A7Z] [8]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Imipramine. Depression [6A70-6A7Z] [8]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Fluoxetine. Depression [6A70-6A7Z] [8]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Nortriptyline. Depression [6A70-6A7Z] [8]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Leuprolide and Escitalopram. Depression [6A70-6A7Z] [9]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Clomipramine. Depression [6A70-6A7Z] [8]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Trazodone. Depression [6A70-6A7Z] [8]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Amitriptyline. Depression [6A70-6A7Z] [8]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Amoxapine. Depression [6A70-6A7Z] [8]
Mirtazapine DML53ZJ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Mirtazapine. Depression [6A70-6A7Z] [8]
Protriptyline DMNHTZI Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Protriptyline. Depression [6A70-6A7Z] [8]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Doxepin. Depression [6A70-6A7Z] [8]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Maprotiline. Depression [6A70-6A7Z] [8]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Venlafaxine. Depression [6A70-6A7Z] [8]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Leuprolide and Citalopram derivative 1. Discovery agent [N.A.] [9]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [8]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Deutetrabenazine. Dystonic disorder [8A02] [8]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Ingrezza. Dystonic disorder [8A02] [8]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Solifenacin. Functional bladder disorder [GC50] [8]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Pentamidine. Fungal infection [1F29-1F2F] [8]
Fluconazole DMOWZ6B Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Fluconazole. Fungal infection [1F29-1F2F] [8]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Ketoconazole. Fungal infection [1F29-1F2F] [8]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [8]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Leuprolide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [18]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Leuprolide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [19]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [8]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [8]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Polyethylene glycol. Irritable bowel syndrome [DD91] [8]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Phenolphthalein. Irritable bowel syndrome [DD91] [9]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Leuprolide and Crizotinib. Lung cancer [2C25] [20]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Leuprolide and Ceritinib. Lung cancer [2C25] [9]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Leuprolide and Osimertinib. Lung cancer [2C25] [21]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Leuprolide and Selpercatinib. Lung cancer [2C25] [8]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Leuprolide and Lumefantrine. Malaria [1F40-1F45] [10]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Leuprolide and Halofantrine. Malaria [1F40-1F45] [22]
Hydroxychloroquine DMSIVND Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Hydroxychloroquine. Malaria [1F40-1F45] [8]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Quinine. Malaria [1F40-1F45] [8]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Primaquine. Malaria [1F40-1F45] [8]
Mefloquine DMWT905 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Mefloquine. Malaria [1F40-1F45] [8]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [8]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Leuprolide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [23]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Leuprolide and Vemurafenib. Melanoma [2C30] [9]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and LGX818. Melanoma [2C30] [8]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Leuprolide and Panobinostat. Multiple myeloma [2A83] [24]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Thalidomide. Multiple myeloma [2A83] [10]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Leuprolide and Siponimod. Multiple sclerosis [8A40] [10]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Leuprolide and Fingolimod. Multiple sclerosis [8A40] [9]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Leuprolide and Ozanimod. Multiple sclerosis [8A40] [25]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Romidepsin. Mycosis fungoides [2B01] [8]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Leuprolide and Nilotinib. Myeloproliferative neoplasm [2A20] [9]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Dasatinib. Myeloproliferative neoplasm [2A20] [8]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Leuprolide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [26]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Leuprolide and Droperidol. Nausea/vomiting [MD90] [9]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Prochlorperazine. Nausea/vomiting [MD90] [8]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Promethazine. Nausea/vomiting [MD90] [8]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Palonosetron. Nausea/vomiting [MD90] [8]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Granisetron. Nausea/vomiting [MD90] [8]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Ondansetron. Nausea/vomiting [MD90] [8]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Entrectinib. Non-small cell lung cancer [2C25] [8]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Leuprolide and Levomethadyl Acetate. Opioid use disorder [6C43] [8]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Lofexidine. Opioid use disorder [6C43] [8]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Rucaparib. Ovarian cancer [2C73] [8]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Dextropropoxyphene. Pain [MG30-MG3Z] [8]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Buprenorphine. Pain [MG30-MG3Z] [8]
Tramadol DMRQD04 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Tramadol. Pain [MG30-MG3Z] [8]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Triclabendazole. Parasitic worm infestation [1F90] [8]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Pimavanserin. Parkinsonism [8A00] [8]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Apomorphine. Parkinsonism [8A00] [8]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Famotidine. Peptic ulcer [DA61] [10]
Vasopressin DMQ2FPC Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Vasopressin. Pituitary gland disorder [5A60-5A61] [8]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Leuprolide and Macimorelin. Pituitary gland disorder [5A60-5A61] [27]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Ritodrine. Preterm labour/delivery [JB00] [13]
Alfuzosin DMZVMKF Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Alfuzosin. Prostate hyperplasia [GA90] [8]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Levomepromazine. Psychotic disorder [6A20-6A25] [8]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Fluphenazine. Psychotic disorder [6A20-6A25] [8]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Triflupromazine. Psychotic disorder [6A20-6A25] [8]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Sorafenib. Renal cell carcinoma [2C90] [8]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Leuprolide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [15]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Quetiapine. Schizophrenia [6A20] [8]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Leuprolide and Mesoridazine. Schizophrenia [6A20] [9]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Leuprolide and Thioridazine. Schizophrenia [6A20] [9]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Aripiprazole. Schizophrenia [6A20] [10]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Leuprolide and Iloperidone. Schizophrenia [6A20] [9]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Paliperidone. Schizophrenia [6A20] [8]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Leuprolide and Haloperidol. Schizophrenia [6A20] [9]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Perphenazine. Schizophrenia [6A20] [8]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Chlorpromazine. Schizophrenia [6A20] [8]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Leuprolide and Clozapine. Schizophrenia [6A20] [9]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Trifluoperazine. Schizophrenia [6A20] [8]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Leuprolide and Ziprasidone. Schizophrenia [6A20] [9]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Risperidone. Schizophrenia [6A20] [8]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Olanzapine. Schizophrenia [6A20] [10]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Leuprolide and Amisulpride. Schizophrenia [6A20] [28]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Asenapine. Schizophrenia [6A20] [8]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Leuprolide and Pimozide. Schizophrenia [6A20] [8]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Vardenafil. Sexual dysfunction [HA00-HA01] [8]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [8]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Leuprolide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [9]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [8]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Pitolisant. Somnolence [MG42] [8]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [8]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Leuprolide and Ibutilide. Supraventricular tachyarrhythmia [BC81] [9]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Leuprolide and Adenosine. Supraventricular tachyarrhythmia [BC81] [9]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Leuprolide and Anagrelide. Thrombocytosis [3B63] [9]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Lenvatinib. Thyroid cancer [2D10] [8]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Leuprolide and Cabozantinib. Thyroid cancer [2D10] [8]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Leuprolide and Papaverine. Tonus and reflex abnormality [MB47] [29]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Tizanidine. Tonus and reflex abnormality [MB47] [8]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Tacrolimus. Transplant rejection [NE84] [8]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Astemizole. Vasomotor/allergic rhinitis [CA08] [8]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [8]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Leuprolide and Disopyramide. Ventricular tachyarrhythmia [BC71] [9]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Leuprolide and Procainamide. Ventricular tachyarrhythmia [BC71] [9]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Propafenone. Ventricular tachyarrhythmia [BC71] [8]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Leuprolide and Flecainide. Ventricular tachyarrhythmia [BC71] [8]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Leuprolide and Amiodarone. Ventricular tachyarrhythmia [BC71] [9]
⏷ Show the Full List of 184 DDI Information of This Drug

References

1 Leuprolide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1175).
3 Hoda MR, Kramer MW, Merseburger AS, Cronauer MV: Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28.
4 FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
7 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 Canadian Pharmacists Association.
10 Cerner Multum, Inc. "Australian Product Information.".
11 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
12 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
13 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
14 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
15 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
16 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
17 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
18 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
19 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
20 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
21 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
22 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
23 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
24 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
25 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
26 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
27 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
28 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
29 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]